According to the 2022 ICC classification [15], 55% of reported SCD-associated AML fulfilled the criteria for AML with myelodysplasia-related or therapy-related features, frequently involving −7/del(7q), −5/del(5q), TP53 mutations, or complex karyotypes. The gene discussed is TP53; the disease is acute myeloid leukemia.